 |
|
|
 |
Protein Patterns May Identify Ovarian Cancer
Scientists from the Food and Drug Administration (FDA) and the National Cancer Institute (NCI)
report today, in a special fast-tracked release in The Lancet, that patterns of proteins found in patients' blood serum may reflect
the presence of disease. In the study, scientists used serum proteins to detect ovarian cancer, even at early stages. They report
that this new diagnostic concept is potentially applicable to any type of disease. more
|
|
Proteomics: Research for the 21st Century
Research about a possible new ovarian cancer screening tool by discovered by Lance Liotta, M.D.,
Ph.D., of the National Cancer Institute (NCI), and Emanuel Petricoin, M.D., of the Food and Drug Administration (FDA),
appeared electronically in The Lancet on 07 February 2002. The scientists were interviewed about the new tool, which employs
a technique called proteomics. The researchers talk about the tool, how it was developed, and its potential applicability to
screening and treatment for ovarian and other cancers. more
|
|
|
|
Proteomics In Clinical Trials
Proteomics - the study of the proteins inside cells - has made its way into cancer trials. New
technologies that allow researchers to visualize thousands of proteins at the same time can reveal patterns that may have
important clinical implications. more
|
|
NIH Panel Outlines Strategies For Managing Tumors Of The Adrenal Glands
A panel convened by the National Institutes of Health issued recommendations to help physicians
evaluate a particular class of tumors of the adrenal glands and determine which should be removed and which should be left
alone. The tumors are known as "incidentalomas" because they are discovered by chance, as a result of testing for other
conditions. Before the advent of sophisticated new imaging technologies, the tumors typically went undetected. more
|
|
Draft National Institutes Of Health State-Of-The-Science Statement: Management of the Clinically
Inapparent Adrenal Mass (Incidentaloma)
NIH Consensus Statements are prepared by a nonadvocate, non-Federal panel of experts, based on presentations by investigators working in areas relevant to the consensus questions. This statement is an independent report of
the panel and is not a policy statement of the NIH or the Federal Government.
This two-and-a-half-day state-of-the-science conference on Management of the Clinically Inapparent Adrenal Mass ("Incidentaloma") was convened on 4-6 February 2002,
to explore and assess the current knowledge regarding adrenal incidentalomas, so that health care providers and the general public can make informed decisions about this important public health issue. more
|
|
|
